Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Chemotherapy-Induced Neuropathy

• Status: Completed
• Trial end date: 2007-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This study was designed to evaluate the safety and efficacy of Cesamet™ in controlling pain in subjects experiencing pain due to chemotherapy-induced neuropathic pain in patients with cancer.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: NEMA Research, Inc.
• Treatments: Nabilone

Criteria

Inclusion Criteria:

• Patients diagnosed with chemotherapy-induced neuropathic pain.

• Chronic daily pain present for at least 2 months.

• On stable analgesic regimen for one month.

• Baseline pain score greater than 40mm on a VAS.

Exclusion Criteria:

• Hypersensitivity to compounds in study drug or similar drugs

• Pregnant or lactating females

• Drug or alcohol abuse

• Unstable medical condition